Strategic Partner(s)

Stuart Maudsley: Receptor Complexity, Aging, and the Limits of Single Target Drugs

Scientific Abstract

GPCR pharmacology has spent decades adding detail to a picture that keeps getting larger. Stuart Maudsley has worked at nearly every scale of that picture, from patch clamping neurokinin receptors as a graduate student to running high dimensional proteomic and informatic analyses of receptor systems across the lifespan.

This conversation follows the idea that has shaped his work: a receptor is not a fixed object with a fixed output but a system that changes by the millisecond and by the decade. In that view, complexity is not an obstacle to therapy, it is the reason therapy is possible. Stuart Maudsley describes dimensional condensation, the practice of turning vast datasets into objects a person can look at and even hold, and the reasoning behind what he calls disease trajectory modifiers, compounds designed for people whose disease is still preclinical.

Running underneath the science is a personal stake. He moved to the National Institute on Aging because his wife's grandfather was living with dementia, and the aging field became the frame for everything he has built since.

About Stuart Maudsley

Stuart Maudsley leads the Receptor Biology Lab at the University of Antwerp, where he is Vice Chair of the Department of Biomedical Sciences and Adjunct Director of the VIB Center for Molecular Neurology. He trained in pharmacology at the University of Leeds, then joined Robert Lefkowitz at Duke University on a Howard Hughes Medical Institute Fellowship before leading the Receptor Biology Section at the MRC Human Reproductive Sciences Unit in Edinburgh.

He went on to head the Receptor Pharmacology Unit at the National Institute on Aging, based at the Johns Hopkins University Medical Center, where he received an NIH Bench to Bedside Translational Research Grant Award. His current work combines mass spectrometry, natural language processing and topological data analysis to build GPCR based therapeutics that act on the gerontological roots of disease, a research stream now forming the basis of the startup HeptOME.

Scientific Themes of the Conversation

Receptors as temporal systems: signaling that shifts across milliseconds and across a lifetime

Low dimensionality versus high dimensionality biology, from one band on a western blot to eighteen thousand proteins on a mass spectrometer

Dimensional condensation and topological data analysis as ways to make enormous datasets legible

Polypharmacology and the case that complex systems respond only to complex inputs

Aging framed as unrepaired damage, with disease as the visible end of a long silent process

The culture of science: attrition, authorship order, and the loss of talented people the field cannot afford

Key Insights from the Conversation

Complexity supplies solutions, it does not remove them

Most people treat biological complexity as a barrier to drug development. Stuart Maudsley argues the opposite, using type 2 diabetes as his example: because every patient's disease is molecularly distinct, the number of ways into the system is larger, not smaller. More dimensions of signaling means more places a therapeutic can enter.

A receptor system cannot hold its shape for eighty years

When he moved into aging research, one question reframed his entire field for him. What is the likelihood that a signaling system of this complexity is maintained with perfect fidelity across eight decades and every millisecond within them? The answer is zero, which means receptor pharmacology has to account for the age of the system it is acting on.

Data becomes understandable when it becomes an object

His lab condenses high dimensional datasets into three dimensional shapes and has 3D printed them so students can hold sixteen thousand data points in one hand. The logic borrows from convergent evolution: if a shark, a dolphin and an ichthyosaur converge on the same form under the same pressures, datasets under the same biological pressure may converge too.

You cannot move a complex system with one finger

Push a single finger into a jelly on a table and the finger sinks while the jelly stays put. Press with a whole hand and the jelly slides. It is his argument against monolithic single target drugs and for designing compounds that touch many nodes of a network at once, gently, relying on the system's own amplification.

The body gets used to being ill

Given long enough, a system drifting out of balance stops recognizing its healthy state as normal and becomes resistant to being returned to it. That reasoning leads to what he calls disease trajectory modifiers: acting during the preclinical phase, which upends the pharmacological convention of treating people only once they are unwell.

Informatics is a difference engine, not an answer generator

He is blunt with students who expect computational analysis to deliver truth. It tells you that two samples differ, not what is actually happening inside them. What he values instead is the zero hit PubMed search, the result with no precedent, where the finding arrives without his prejudice attached to it.

Changing scientific language every five years has a cost he accepts

A talk he wandered into at the NIH library on natural language processing rewrote how he analyzes biomedical data. He describes each such shift as adopting a new language, and is candid that the pattern is a career disadvantage: people are told to pick one thing and stay with it. He calls the reinvention painful and brutal, and does it anyway.

Episode Timeline

00:00 Introduction

02:14 Star Wars, a BBC film about the discovery of DNA, and the choice of pharmacology

07:29 Writing to Robert Lefkowitz, and what a lab full of people talking in corridors actually taught him

20:10 Why pharmacology: a science that has to produce something

29:25 Natural language processing, and reading millions of papers without reading any of them

38:44 From low dimensionality to high dimensionality, and the eighteen thousand proteins behind every western blot

46:13 Dimensional condensation: turning datasets into objects students can hold

58:50 How aging entered the work, and why receptor systems cannot stay the same for a lifetime

01:16:58 The encrypton idea: how a cell decodes many ligands arriving at once

01:31:27 Drugs as software for a complex machine, and the jelly on the table

01:45:49 Disease trajectory modifiers: giving compounds to people who are not yet ill

02:29:13 Advice for young scientists: make the decision, then own it

03:18:29 Work, family, and the culture that keeps pushing women out of science

Timestamps were generated using AI for readability.

Selected Quotes

"Talking beats working hard every day of the week, because you thrash out and you get the ideas and you write them on a board and things spark into your brain."

"Every single year we realize there are a hundred more onion layers to go. It's never gonna stop."

"A lot of people would see extra complexity as a problem. Actually what it means is more potential solutions, because not everyone will be disrupted in the same way."

"My goal as a pharmacologist now is to give drugs to people that aren't unwell. That would be a crazy concept many years ago."

Guest Links

Maudsley Lab: https://www.uantwerpen.be/nl/personeel/stuart-maudsley/

LinkedIn: https://www.linkedin.com/in/stuart-maudsley-18a58328/

Google Scholar: https://scholar.google.com/citations?user=KQ6pwbEAAAAJ&hl=en&oi=ao

ResearchGate: https://www.researchgate.net/profile/Stuart-Maudsley

Maudsley Lab on Facebook: https://www.facebook.com/MaudsleyLab/

Receptor Biology Lab Facebook Group: https://www.facebook.com/groups/622756024785459

Twitter: https://twitter.com/StuartMaudsley

Semantic Scholar: https://www.semanticscholar.org/author/Stuart-Maudsley/2308781

Instagram: https://www.instagram.com/receptorbiologylab/?hl=en

Neurotree: https://neurotree.org/beta/peopleinfo.php?pid=780703